See more : Chd Chemicals Limited (CHDCHEM.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Genenta Science S.p.A. (GNTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genenta Science S.p.A., a leading company in the Biotechnology industry within the Healthcare sector.
- BG Medicine, Inc. (BGMD) Income Statement Analysis – Financial Results
- SciClone Pharmaceuticals (Holdings) Limited (6600.HK) Income Statement Analysis – Financial Results
- Lion Travel Service Co., Ltd. (2731.TW) Income Statement Analysis – Financial Results
- Compagnie d’Entreprises CFE SA (CFEB.BR) Income Statement Analysis – Financial Results
- The Lakshmi Mills Company Limited (LAKSHMIMIL.BO) Income Statement Analysis – Financial Results
Genenta Science S.p.A. (GNTA)
About Genenta Science S.p.A.
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 41.58K | 6.03K | 5.08K | 1.77K | 0.00 |
| Gross Profit | -41.58K | -6.03K | -5.08K | -1.77K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.47M | 5.34M | 3.39M | 4.69M | 3.70M |
| General & Administrative | 5.26M | 5.71M | 2.30M | 901.77K | 921.52K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.26M | 5.71M | 2.30M | 901.77K | 921.52K |
| Other Expenses | 0.00 | 242.55K | -150.00K | 5.97K | 36.33K |
| Operating Expenses | 11.73M | 11.04M | 5.54M | 5.59M | 4.62M |
| Cost & Expenses | 11.73M | 11.04M | 5.54M | 5.59M | 4.62M |
| Interest Income | 0.00 | 36.99 | 11.72 | 7.75 | 9.55 |
| Interest Expense | 0.00 | 0.00 | 11.72K | 7.75K | 9.55K |
| Depreciation & Amortization | 42.45K | 6.03K | 5.08K | 1.77K | 4.62M |
| EBITDA | -11.69M | -11.04M | -5.68M | -5.59M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -11.73M | -11.04M | -5.69M | -5.59M | -4.62M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 87.49K | 2.57M | 157.94K | -1.79K | 26.78K |
| Income Before Tax | -11.65M | -8.48M | -5.53M | -5.59M | -4.60M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -4.85M | 31.37K | 13.72K | 9.55K |
| Net Income | -11.65M | -3.62M | -5.56M | -5.61M | -4.61M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.64 | -0.20 | -0.31 | -0.31 | -0.25 |
| EPS Diluted | -0.64 | -0.20 | -0.31 | -0.31 | -0.25 |
| Weighted Avg Shares Out | 18.22M | 18.22M | 18.22M | 18.12M | 18.12M |
| Weighted Avg Shares Out (Dil) | 18.22M | 18.22M | 18.22M | 18.12M | 18.12M |
Genenta to Participate at Upcoming Investor Conferences
U.S. IPO Weekly Recap: 6 IPOs Debut Ahead Of The Shortened Holiday Week
Genta Provides Comprehensive Update of Research and Development Activities
Source: https://incomestatements.info
Category: Stock Reports